Rice Hall James & Associates LLC Raises Stock Holdings in Evolus, Inc. $EOLS

Rice Hall James & Associates LLC increased its holdings in shares of Evolus, Inc. (NASDAQ:EOLS) by 8.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,254,819 shares of the company’s stock after acquiring an additional 101,375 shares during the period. Rice Hall James & Associates LLC’s holdings in Evolus were worth $5,157,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of EOLS. Larson Financial Group LLC grew its position in Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus during the fourth quarter worth $34,000. Wexford Capital LP purchased a new stake in shares of Evolus during the third quarter valued at $37,000. Aquatic Capital Management LLC purchased a new stake in shares of Evolus during the third quarter valued at $48,000. Finally, State of Wyoming purchased a new stake in shares of Evolus during the fourth quarter valued at $63,000. 90.69% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EOLS has been the topic of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a research note on Wednesday, June 17th. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Stock Down 0.2%

Shares of NASDAQ:EOLS opened at $5.98 on Friday. The business’s 50 day moving average is $6.50 and its 200 day moving average is $5.48. The stock has a market cap of $393.84 million, a P/E ratio of -8.93 and a beta of 1.32. Evolus, Inc. has a 52-week low of $3.86 and a 52-week high of $9.72.

Evolus (NASDAQ:EOLS) last issued its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same period in the previous year, the business posted ($0.30) earnings per share. On average, sell-side analysts anticipate that Evolus, Inc. will post -0.38 EPS for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.